AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wootton, M.
Right arrow Articles by MacGowan, A. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wootton, M.
Right arrow Articles by MacGowan, A. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2005, p. 3982-3983, Vol. 49, No. 9
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.9.3982-3983.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Evidence for Reduction in Breakpoints Used To Determine Vancomycin Susceptibility in Staphylococcus aureus


   LETTER
Top
 Letter
References
 
Questions regarding the prevalence and clinical significance of both vancomycin-intermediate Staphylococcus aureus (VISA) and, more importantly, heterogeneous VISA (hVISA) are difficult to address, mainly due to the lack of accurate methods and guidelines for the identification of hVISA. VISA strains have been isolated from many areas of the world but are few in number (<30); however, hVISA strains appear more common. Current susceptibility techniques, along with CSLI (S/I/R-4/8-16/32) and EUCAST (S/R-4/8) recommended breakpoints, are generally inadequate for the identification of hVISA (10, 11).

Although glycopeptides remain the recommended therapy for patients with methicillin-resistant Staphylococcus aureus infection, treatment failure is common, with 10 to 20% in cases of endocarditis and 40% in lower respiratory tract infections (3, 6). Treatment failure cause is not fully understood; however, clinical failures have been reported for patients with VISA (8, 1) and, more recently, for hVISA infection (2, 12, 13). Evidence suggests that hVISA infections are clinically relevant, with patients with hVISA bacteremia more likely to have high-bacterial-load infections, vancomycin treatment failure, bacteremia for >7 days, and a significantly higher mortality (63%) than those patients infected with vancomycin-susceptible methicillin-resistant S. aureus (VSSA) bacteremia (12%) (4, 5). More recently, treatment failure in patients with infections caused by strains with MICs within the susceptibility range (≤2 mg/liter) has been reported (9). Also, current CDC guidelines for testing S. aureus with vancomycin recommend that strains exhibiting MICs of ≤2 mg/liter plus growth on vancomycin screening plates are possibly VISA (www.cdc.gov/ncidod/hip/vanco/vanco.htm). These data suggest that current susceptibility breakpoints for glycopeptides require review.

We used an international collection of VSSA, VISA, and hVISA strains with CSLI agar dilution techniques to determine vancomycin MICs (7). Each data set was compared with a view to recalculating a vancomycin breakpoint. VISA and hVISA phenotypes were identified by the more accurate modified population analysis method (population analysis profile-area under the curve) (14).

Of 106 glycopeptide-susceptible S. aureus strains, 10.4% had vancomycin MICs of 0.5 mg/liter, 85.8% had vancomycin MICs of 1 mg/liter, and 3.8% had vancomycin MICs of 2 mg/liter. The percentage of isolates classified as susceptible by the CSLI and EUCAST breakpoint (4 mg/liter) and a reduced breakpoint (2 mg/liter) was 100%, suggesting that no false positives would emerge from breakpoint reduction. Of 20 VISA strains, 55% exhibited vancomycin MICs of 4 mg/liter and 45% had vancomycin MICs of 8 mg/liter. Using the current breakpoint, 55% are classified as susceptible and 45% as intermediate. However, when using the reduced breakpoint, 100% are classified as intermediate (CSLI) or resistant (EUCAST). Of 157 hVISA strains, 2% exhibited vancomycin MICs of 1 mg/liter, 80.2% had vancomycin MICs of 2 mg/liter, and 17.8% had vancomycin MICs of 4 mg/liter. Using the current breakpoint, 100% are classified as susceptible; however, when using the reduced breakpoint, 82.2% would still be classified as susceptible but 17.8% would be classified as intermediate (CSLI) or resistant (EUCAST). By use of the reduced breakpoint, the correct classifications of hVISA and VISA would increase from 45% and 0% to 100% and 17.2%, respectively. Distribution of vancomycin MICs in the different phenotypes shows that 2 mg/liter is the most predominant in hVISA (Fig. 1). The effect of a reduced breakpoint on the classification of coagulase-negative staphylococci would be minimal, with only 1.56% currently exhibiting a vancomycin MIC of 4 mg/liter (www.EUCAST.org). This evidence supports a modification of the contemporary interpretative guidelines for vancomycin susceptibility testing from ≤4 mg/liter for susceptible isolates to ≤2 mg/liter.



View larger version (19K):
[in this window]
[in a new window]
  		FIG. 1. Frequency distribution of vancomycin MICs in VSSA, hVISA, and VISA strains.

 


   REFERENCES
Top
 Letter
 References
 

  1. Andrade-Baiocchi, S., M. C. B. Tognim, O. C. G. Baiocchi, and H. S. Sader. 2003. Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterisation. Diagn. Microbiol. Infect. Dis. 45:149-152.[CrossRef][Medline]
  2. Ariza, J., M. Pujol, J. Cabo, C. Pena, N. Fernandez, J. Linares, J. Ayats, and F. Gudiol. 1999. Vancomycin in surgical infections due to methicillin resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 353:1587-1588.[CrossRef][Medline]
  3. Bayer, A. S. 1993. Infective endocarditis. Clin. Infect. Dis. 17:313-320.[Medline]
  4. Charles, P. G. P., P. B. Ward, P. D. R. Johnson, B. P. Howden, and M. L. Grayson. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448-451.[CrossRef][Medline]
  5. Fridkin, S. K., J. C. Hageman, L. McDougal, J. Mohammed, W. R. Jarvis, T. M. Perl, and F. Tenover. 2003. Epidemiological and microbiological characterisation of infections caused by Staphylococcus aureus with reduced susceptibilities to vancomycin, 1997-2001. Clin. Infect. Dis. 36:429-439.[CrossRef][Medline]
  6. Moise, P. A., and J. J. Schentag. 2001. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int. J. Antimicrob. Agents 16:31-34.
  7. National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial susceptibility testing. M100-S13. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  8. Ploy, M. C., C. Grélaud, C. Martin, L. de Lumley, and F. Denis. 1998. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351:1212.[Medline]
  9. Sakoulas, G., P. A. Moise-Broder, J. Schentag, A. Forrest, R. C. Moellering, Jr., and G. M. Eliopoulos. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402.[Abstract/Free Full Text]
  10. Tenover, F. C., M. V. Lancaster, B. C. Hill, C. D. Steward, S. A. Stocker, G. A. Hancock, C. M. O'Hara, N. C. Clark, and K. Hiramatsu. 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 36:1020-1027.[Abstract/Free Full Text]
  11. Walsh, T. R., A. Bolmström, A. Qwärnström, P. Ho, M. Wootton, R. A. Howe, A. P. MacGowan, and D. Diekema. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444.[Abstract/Free Full Text]
  12. Ward, P. B., P. D. Johnson, E. A. Grabsch, B. C. Mayall, and M. L. Grayson. 2001. Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Med. J. Aust. 175:480-483.[Medline]
  13. Woods, C. W., A. C. Cheng, V. G. Fowler, M. Moorefield, J. Frederick, G. Sakoulas, V. G. Meka, F. C. Tenover, P. Zwadyk, and K. H. Wilson. 2004. Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin. Clin. Infect. Dis. 38:1188-1191.[CrossRef][Medline]
  14. Wootton, M., R. A. Howe, R. Hillman, T. R. Walsh, P. M. Bennett, and A. P. MacGowan. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403.[Abstract/Free Full Text]
Mandy Wootton*
T. R. Walsh
A. P. MacGowan
B.C.A.R.E.
Southmead Hospital
Bristol, United Kingdom

* Phone: 44 117 9287526, Fax: 44 117 9287896, E-mail: mandy.wootton{at}bristol.ac.uk

Antimicrobial Agents and Chemotherapy, September 2005, p. 3982-3983, Vol. 49, No. 9
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.9.3982-3983.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wootton, M.
Right arrow Articles by MacGowan, A. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wootton, M.
Right arrow Articles by MacGowan, A. P.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS